MS & Immune Disorders

Filter Your Results

 

News

 

Positive Results from Phase 2 Clinical Trials of Evobrutinib for Multiple Sclerosis

Friday, March 01, 2019—After 24 weeks of treatment, patients treated with 75 mg of evobrutinib (EMD Serono, Rockland, MA) 2 or 4 times per day had significantly fewer T1 gadolinium-enhancing (Gd+) l…

New Drug Application Novel for Oral Fumarate Accepted by Food and Drug Administration

Monday, February 25, 2019—The Food and Drug Administration (FDA) has accepted an application for diroximel fumarate (BIIB098; Alkermes, Waltham, MA and Biogen, Cambridge, MA) for the treatment of relap…

Multiple Sclerosis Prevalence May Be Twice As High as Previously Thought

Tuesday, February 19, 2019—A study published in the journal Neurology suggests prevalence of multiple sclerosis (MS) in the US is 913,925 -- more than twice the previous estimate of 400,000 pe…

Stem-Cell Transplants Delayed Disease Progression of Multiple Sclerosis

Friday, January 25, 2019—January 25, 2019 -- As published in JAMA, interim results of the phase 2 MIST trial (NCT00273364) show that stem-cell treatment resulted in a significantly prolonged time…

Breakthrough Device Designation Granted to Brain-Monitoring Technology

Wednesday, January 09, 2019—The Food and Drug Administration has granted breakthrough device designation to a brain health monitoring technology (Neurametrix; San Francisco, CA). The approved use is moni…

Inebilizumab Meets Primary and Secondary Endpoints for Treatment of Neuromyelitis Optica Spectrum Disorder

Friday, January 04, 2019—In a global trial of inebilizumab (Viela Bio, Gaithersberg, MD) for the treatment of patients with neuromyelitis optica spectrum disorder (NMOSD), the drug met its primary and…

American Academy of Neurology Call for Uniformity in Brain Death Standards

Thursday, January 03, 2019—Noting that only 1 state, Nevada, has adopted legislation requiring use of medically accepted guidelines for determining brain death, the American Academy of Neurology (AAN) i…

Gray Matter Atrophy in Multiple Sclerosis May Occur Independently of Clinically Effective Treatment

Friday, December 21, 2018—Once thought to be a disease only of white matter, the myelin sheath of oligoglia, it is now accepted that multiple sclerosis (MS) affects nerve cells themselves, the gray mat…

 
 

Contact Info

For advertising rates and opportunities:
Wendy Terry
Publisher
217-652-3859
wterry@bmctoday.com

About Practical Neurology

Launched in 2002, Practical Neurology is a publication uniquely dedicated to presenting current approaches to patient management, synthesis of emerging research and data, and analysis of industry news with a goal to facilitate practical application and improved clinical practice for all neurologists. Our straightforward articles give neurologists tools they can immediately put into practice.

 
  • BRYN MAWR COMMUNICATIONS III, LLC